X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of “Hold” from Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned an average recommendation of “Hold” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $34.50.

XFOR has been the subject of several research reports. Zacks Research cut X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of X4 Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen lowered shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 30th. Finally, Stifel Nicolaus set a $10.00 price objective on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, December 5th.

Institutional Trading of X4 Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Nantahala Capital Management LLC bought a new stake in shares of X4 Pharmaceuticals during the third quarter valued at approximately $7,621,000. Rosalind Advisors Inc. acquired a new stake in X4 Pharmaceuticals during the third quarter worth $5,283,000. Deep Track Capital LP bought a new stake in X4 Pharmaceuticals in the 3rd quarter valued at $3,839,000. Kingdon Capital Management L.L.C. raised its stake in shares of X4 Pharmaceuticals by 300.0% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 933,332 shares of the company’s stock valued at $3,192,000 after buying an additional 700,000 shares in the last quarter. Finally, Boothbay Fund Management LLC acquired a new position in shares of X4 Pharmaceuticals in the 3rd quarter valued at $1,176,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Trading Up 0.3%

X4 Pharmaceuticals stock opened at $3.70 on Friday. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $24.30. The company has a debt-to-equity ratio of 1.23, a quick ratio of 5.48 and a current ratio of 5.65. The firm has a market capitalization of $323.53 million, a PE ratio of -0.37 and a beta of 0.41. The business’s 50-day simple moving average is $3.82 and its 200-day simple moving average is $3.32.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Wednesday, November 5th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.10. The firm had revenue of $1.77 million for the quarter, compared to analyst estimates of $2.05 million. X4 Pharmaceuticals had a negative return on equity of 343.67% and a negative net margin of 279.86%. Equities research analysts forecast that X4 Pharmaceuticals will post -0.68 earnings per share for the current year.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.